The very reason United Therapeutics Corp. (NASDAQ: UTHR) exists is because there wasn’t an effective treatment for Martine Rothblatt’s daughter when she was diagnosed with pulmonary arterial hypertension more than 20 years ago.
Rothblatt recently told investors the Silver Spring-based pharmaceutical has found the market a bit more crowded these days. In December, the Food and Drug Administration approved Actelion Pharmaceuticals LTD’s Uptravi to treat adults with pulmonary arterial hypertension.
{iframe}http://www.bizjournals.com/washington/blog/techflash/2016/03/united-therapeutics-sees-stepped-up-competition.html{/iframe}